American Society of Hirudotherapy

Heparin-induced thrombocytopenia.

Research article published in Hematology/oncology clinics of North America (2007)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical TrialsWarkentin · Hematology/oncology clinics of North America, 2007

Abstract

Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug effect that is characterized by platelet activation, hypercoagulability, and a resulting increased risk for thrombosis, both venous and arterial. This disorder is autoimmune-like, because the target antigen is a multimolecular complex of the "self" protein, platelet factor 4, and heparin. HIT usually begins 5 to 10 days after starting heparin, especially when administered intra- or perioperatively, although a rapid onset of thrombocytopenia can occur if heparin is given to a patient with circulating HIT antibodies that resulted from a recent heparin exposure. The clinical diagnosis is supported if heparin-dependent, platelet-activating antibodies are detectable. Treatment includes cessation of heparin and use of an alternative non-heparin anticoagulant, such as danaparoid, lepirudin, or argatroban. Warfarin must be avoided or postponed, as the acute phase of HIT poses a high risk for coumarin necrosis, particularly limb loss due to venous limb gangrene.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tReview
Indexed MeSH termsAntibodiesAnticoagulantsHeparinHumansPlatelet ActivationPlatelet Factor 4Thrombocytopenia

Summary

Heparin-induced thrombocytopenia.

Why This Matters for Hirudotherapy

This review examines the pathophysiology and treatment of heparin-induced thrombocytopenia (HIT), an immune-mediated adverse drug effect with a high risk of thrombosis. It discusses the cessation of heparin and the initiation of alternative anticoagulants, specifically mentioning lepirudin alongside danaparoid and argatroban. Because lepirudin is a recombinant derivative of the leech salivary anticoagulant hirudin, this study touches on the pharmaceutical legacy of leeches. Nevertheless, the article does not evaluate live leech therapy or natural secretome extracts, resulting in an indirect link to the core domain of hirudotherapy.

Citation

Heparin-induced thrombocytopenia.

Warkentin · Hematology/oncology clinics of North America, 2007

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.